Medivation (MDVN) Tops Q2 EPS by 13c

Go back to Medivation (MDVN) Tops Q2 EPS by 13c

Medivation Reports Second Quarter 2015 Financial Results

August 6, 2015 4:10 PM EDT

SAN FRANCISCO, CA -- (Marketwired) -- 08/06/15 -- Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the second quarter ended June 30, 2015. U.S. net sales of XTANDI (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $298.4 million for the quarter (+108% vs. prior year). Second quarter U.S. net sales increased by 33% compared with first quarter 2015 net sales of $224.0 million. We estimate second quarter 2015 unit demand increased by a low- to mid-teens percentage rate, compared with unit demand in the first quarter 2015. In addition, based on information provided by Astellas, a lower gross-to-net... More